Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01720043 · ClinicalTrials.gov registry record · Phase 2
Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients
A Phase 2 study, sponsored by University of Utah.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT01720043: Clinical Trial Phase 2 study, sponsored by University of Utah.
NCT01720043 is a Phase 2 study that was terminated before completion, run by University of Utah. The registered enrollment target is 8 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01720043, a Phase 2 study, was terminated before completion, sponsored by University of Utah.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
To evaluate the effect of VELCADE on platelet aggregation at baseline, 24 hours and 48 hours after infusion in patients with multiple myeloma
Primary Outcome
Effect of VELCADE at 1.0-1.3 mg/m2 dose on platelet aggregation at 24 and 48 hour post-infusion in patients with multiple myeloma. The following components of platelet aggregation were evaluated at varying levels: Collagen, Adenine di-Phosphate (ADP), Arachidonic acid, and Ristocetin.
Interventions
- DRUG Velcade
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2013-07 |
| Est. Completion | 2017-07 |
| Phase | Phase 2 |
Why NCT01720043 stopped before completion
NCT01720043 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which Velcade is the first listed.
NCT01720043 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01720043 about?
NCT01720043 is a clinical study titled "Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients". To evaluate the effect of VELCADE on platelet aggregation at baseline, 24 hours and 48 hours after infusion in patients with multiple myeloma
What is the current status of trial NCT01720043?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2013-07. Estimated completion is 2017-07.
What interventions are being tested in trial NCT01720043?
The interventions under investigation include: Velcade (DRUG).
Who is sponsoring clinical trial NCT01720043?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01720043's enrollment target sits among peer trials
8 1990th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia